Results 281 to 290 of about 716,083 (340)

PRDM1+ Malignant Cells Mediate an Immunosuppressive Landscape and Resistance to Neoadjuvant Chemoradiotherapy and Immunotherapy in Esophageal Squamous Cell Carcinoma

open access: yesAdvanced Science, EarlyView.
Integrated scRNA‐seq, scTCR‐seq analysis, and functional assays identify PRDM1+ malignant epithelial cells with hyper lipid peroxidation characteristics that demonstrate reduced responsiveness to the nICRT treatment. Principal factor PRDM1 activates cysteine metabolism genes to modulate lipid peroxidation (an intrinsic cellular pathway related to ...
Dijian Shen   +12 more
wiley   +1 more source

Soft‐Drug‐Inspired MnSTF Nano‐Adjuvant for Safe and Synergistic cGAS–STING Activation in Tumor Immunotherapy

open access: yesAdvanced Science, EarlyView.
This study introduces MnSTF, a soft‐drug‐inspired nanoadjuvant that overcomes the systemic toxicity of STING agonists. Through Mn2+ coordination with an ENPP1 inhibitor, it enables safe cGAS‐STING activation, remodels the tumor immune microenvironment, and synergizes with radiotherapy or vaccines to elicit robust antitumor immunity.
Guangfei Sun   +8 more
wiley   +1 more source

AI‐Driven Acceleration of Fluorescence Probe Discovery

open access: yesAdvanced Science, EarlyView.
We present PROBY, an AI model trained on large‐scale datasets to predict key photophysical properties and accelerate the discovery of target‐specific fluorescent probes. By screening a target‐annotated library, PROBY identifies candidate probes for diverse targets and could guide probe optimization, enabling a range of in vitro and in vivo imaging ...
Xuefeng Jiang   +18 more
wiley   +1 more source

Default mode network tau predicts future clinical decline in atypical early Alzheimer's disease. [PDF]

open access: yesBrain
Katsumi Y   +10 more
europepmc   +1 more source

Transcranial focused ultrasound targeting the default mode network for the treatment of depression. [PDF]

open access: yesFront Psychiatry
Schachtner JN   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy